2024
The management of heart failure cardiogenic shock: an international RAND appropriateness panel
Williams S, Kalakoutas A, Olusanya S, Schrage B, Tavazzi G, Carnicelli A, Montero S, Vandenbriele C, Luk A, Lim H, Bhagra S, Ott S, Farrero M, Samsky M, Kennedy J, Sen S, Agrawal R, Rampersad P, Coniglio A, Pappalardo F, Barnett C, Proudfoot A. The management of heart failure cardiogenic shock: an international RAND appropriateness panel. Critical Care 2024, 28: 105. PMID: 38566212, PMCID: PMC10988801, DOI: 10.1186/s13054-024-04884-5.Peer-Reviewed Original ResearchConceptsTemporary mechanical circulatory supportClinical practiceHF-CSCritical care admissionMulti-disciplinary panelRandomised controlled trialsClinical guidelinesAcutely decompensated chronic HFBackgroundObservational dataControlled trialsDecompensated chronic HFAppropriate methodologiesTrial designInternational expertsConclusionThis studyClinical trial designMechanical circulatory supportChronic HFCardiogenic shockClinical trialsAppropriate panelThoracic ultrasoundCirculatory supportLos AngelesPractice
2023
Risk Prediction for Heart Failure Patients Admitted to the Intensive Care Unit Insights From REVeAL-HF
O’Connor K, Yamamoto Y, Sen S, Samsky M, Wilson F, Desai N, Ahmad T, Fuery M. Risk Prediction for Heart Failure Patients Admitted to the Intensive Care Unit Insights From REVeAL-HF. JACC Heart Failure 2023, 11: 727-728. PMID: 37052546, DOI: 10.1016/j.jchf.2023.01.021.Peer-Reviewed Original Research
2022
Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial
Ghazi L, O'Connor K, Yamamoto Y, Fuery M, Sen S, Samsky M, Riello R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial. American Heart Journal 2022, 257: 111-119. PMID: 36493842, DOI: 10.1016/j.ahj.2022.12.002.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyAcute heart failureHeart failurePragmatic trialElectronic health recordsSubstantial health care costsBest practice advisoryReduced ejection fractionUsual care armHealth recordsTime of dischargeEvidence-based careHealth care costsClinical decision support systemAHF patientsCare armEligible patientsHF hospitalizationInpatient initiationCardiovascular deathMedication classesEjection fractionMedical therapyPrimary outcomePractice advisory
2021
Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
Greene SJ, Choi S, Lippmann SJ, Mentz RJ, Greiner MA, Hardy NC, Hammill BG, Luo N, Samsky MD, Heidenreich PA, Laskey WK, Yancy CW, Peterson PN, Curtis LH, Hernandez AF, Fonarow GC, O'Brien EC. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Journal Of The American Heart Association 2021, 10: e021459. PMID: 34350772, PMCID: PMC8475054, DOI: 10.1161/jaha.121.021459.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAminobutyratesAngiotensin II Type 1 Receptor BlockersBiphenyl CompoundsDrug CombinationsFemaleHeart FailureHospitalizationHumansMaleMedicareNeprilysinPatient DischargeProtease InhibitorsRegistriesRisk AssessmentRisk FactorsStroke VolumeTime FactorsTreatment OutcomeUnited StatesValsartanVentricular Function, LeftConceptsEnzyme inhibitors/angiotensin II receptor blockersSacubitril/valsartanAngiotensin II receptor blockersII receptor blockersHeart failure hospitalizationReduced ejection fractionCause hospitalizationReceptor blockersFailure hospitalizationCause mortalityOlder patientsDischarge prescriptionsEjection fractionHeart failureAngiotensin-converting enzyme inhibitors/angiotensin II receptor blockersGuidelines-Heart Failure registryRoutine US clinical practiceMedicare beneficiaries ageUS clinical practiceHFrEF medicationsPostdischarge mortalityPostdischarge outcomesClinical outcomesRandomized trialsClinical effectivenessEfficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial
Berg DD, Samsky MD, Velazquez EJ, Duffy CI, Gurmu Y, Braunwald E, Morrow DA, DeVore AD. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. Circulation Heart Failure 2021, 14: e007034. PMID: 33530704, PMCID: PMC7908815, DOI: 10.1161/circheartfailure.120.007034.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAminobutyratesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBiphenyl CompoundsCardiotonic AgentsCardiovascular DiseasesChronic DiseaseDrug CombinationsEnalaprilGlomerular Filtration RateHeart FailureHospitalizationHumansHyperkalemiaHypotensionIntensive Care UnitsNatriuretic Peptide, BrainPeptide FragmentsRenal InsufficiencyRiskValsartanConceptsAcute decompensated heart failureSacubitril/valsartanDecompensated heart failureHeart failureCardiovascular deathHigh-risk subpopulationsIndex hospitalizationSymptomatic hypotensionRenal functionSafety outcomesBaseline systolic blood pressureBaseline NT-proBNPPIONEER-HF trialDouble-blind trialHigh-risk patientsGlomerular filtration rateSystolic blood pressureHigh-risk subgroupsRelative risk reductionRisk-benefit profileLow-risk subgroupsHospital initiationInotrope usePIONEER-HFNT-proBNP